- Safety Review Committee (SRC) approves single dose of 3 mg for third cohort of PMC-403 Phase 1 trial
Daejeon,
PMC-403 is a novel TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels. TIE2 receptors, expressed on endothelial cells, are involved in vascular normalization processes such as angiogenesis and intercellular adhesion.
This Phase 1 trial is targeted at patients with neovascular age-related macular degeneration who are no longer responding to standard anti-VEGF therapies. With the SRC decision, the trial will advance to the highest single dose cohort (4 mg) and the first multiple ascending dose cohort (3 mg), potentially providing more advanced data from this Phase 1 study.
Dr. Weon Sup Lee, R&D Director and CTO of Abcine PharmacyHe said: “Despite standard anti-VEGF treatments, many patients with neovascular age-related macular degeneration continue to experience vision loss and retinal vascular leakage. We are committed to delivering an innovative new medicine with a differentiated mode of action to these patients.” He added: “If final safety is confirmed in this Phase 1 trial, it will increase the likelihood of advancing to Phase 2, paving the way for commercialization of this treatment.”
Macular degeneration is a leading cause of blindness caused by age-related damage to the retina, particularly due to abnormal blood vessels in the macula. The aging of the global population has led to a rapid increase in cases of macular degeneration, and current standard treatments with anti-VEGF inhibitors are insufficient for a complete treatment. Consequently, there is a growing demand for new mechanism-based therapies.
Once From PharmAbcine PMC-403 ensures safety in the highest dose cohort (4 mg) and could play a crucial role in the treatment of macular degeneration. As the likelihood of moving to Phase 2 clinical trials increases, PMC-403 is expected to provide a new treatment option for patients with macular degeneration worldwide.
About Abcine Pharmacy Inc.
Abcine Pharmacy is a public clinical-stage company developing next-generation IgG-based therapies to treat cancer, neovascular eye diseases and unmet vascular needs.
The Company’s main product line includes the clinical assets olinvacimab, PMC-403 and PMC-309.
Olinvacimab, the Company’s lead asset, is conducting a Phase II trial in combination with MSD’s pembrolizumab for patients with mTNBC in
PMC-403 is a novel TIE2-activating antibody that stabilizes disorganized, leaky, and dysfunctional pathological vessels and can be used for blood vessel-related ocular diseases including wet AMD (NASDAQ:) (age-related macular degeneration). PMC-403 is currently in Phase 1 trial for patients with neovascular AMD in
PMC-309, a novel anti-VISTA IgG antagonist under pan pH conditions, is an immune checkpoint regulator that targets MDSCs (myeloid-derived suppressor cells) and M2 macrophages that play a pivotal role in maintaining the immunosuppressive tumor microenvironment (E). Phase I is ongoing at a multicenter site.
PMC-005 is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and can be applied to various modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell activator, and radioimmunotherapy.
For additional information on Abcine PharmacyVisit http://www.pharmabcine.com or follow us on YouTube and LinkedIn.
For licensing agreements, joint ventures, co-development and research collaboration or antibody discovery inquiries, please contact:
Business Development Team
Email: bd@pharmabcine.com
Office line: +82 70 4279 5100
For investor relations and public relations inquiries, please contact:
Public Relations and Investment Team
Email: pmc_dis@pharmabcine.com